Drug class · Oncology & immunology
Monoclonal antibodies Drug Codes & NDCs
Products the FDA listing tags with the monoclonal-antibody chemical structure class, plus the PD-1, PD-L1 and CD20 antibody classes. Not every antibody product carries these tags, so treat this list as a starting point rather than a complete census.
Most-listed names in this class
Ranked by the number of FDA listings, which reflects labelers and package variety — not sales or prescribing.
HCPCS references in Med-Code’s directory
- AtezolizumabJ9022Injection, atezolizumab, 10 mg
- DaratumumabJ9145Injection, daratumumab, 10 mg
- DupilumabNo specific codeMed-Code's directory has no drug-specific HCPCS code for dupilumab. It is usually self-administered and billed by NDC through a pharmacy benefit.
- DurvalumabJ9173Injection, durvalumab, 10 mg
- NivolumabJ9299Injection, nivolumab, 1 mg
- RituximabJ9312Injection, rituximab, 10 mg
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Adalimumabadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-325 |
| Adalimumabadalimumab-adaz | Adalimumab 40 mg/.4mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-327 |
| Adalimumabadalimumab-adaz | Adalimumab 20 mg/.2mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-332 |
| Adalimumabadalimumab-adaz | Adalimumab 10 mg/.1mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-391 |
| Adalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Cordavis Limited | 83457-186 |
| Adalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Cordavis Limited | 83457-187 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | Amgen, Inc | 55513-399 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | Amgen, Inc | 55513-400 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | Amgen, Inc | 55513-410 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.4mL | InjectionSubcutaneous | Amgen, Inc | 55513-411 |
| Amjevitaadalimumab-atto | Adalimumab 10 mg/.2mL | InjectionSubcutaneous | Amgen, Inc | 55513-413 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen, Inc | 55513-479 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Amgen, Inc | 55513-480 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Amgen, Inc | 55513-481 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen, Inc | 55513-482 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-399 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-400 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-479 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-481 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-482 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | Nuvaila Limited | 84612-399 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Nuvaila Limited | 84612-479 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Nuvaila Limited | 84612-481 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Nuvaila Limited | 84612-482 |
| Bavencioavelumab | Avelumab 20 mg/mL | Injection, Solution, ConcentrateIntravenous | EMD Serono, Inc. | 44087-3535 |